Ono/BMS Highlight Low Rates Of Serious Infection With Orencia
This article was originally published in PharmAsia News
Ono and Bristol Myers Squibb said July 4 that the rate of serious infection, a current problem associated with the administration of biological formulations, is low for biological rheumatoid arthritis drug Orencia (abatacept).
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.